Yumanity Therapeutics Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 6

Employees

  • Latest Deal Type
  • M&A

Yumanity Therapeutics General Information

Description

Developer of transformative brain-penetrating small molecule drugs designed for the treatment of neurodegenerative diseases caused by protein misfolding. The company is focused on the discovery and development of innovative, disease-modifying therapies for patients with Parkinson's disease and related disorders, amyotrophic lateral sclerosis and Alzheimer's disease.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 40 Guest Street
  • Suite 4410
  • Boston, MA 02135
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • 40 Guest Street
  • Suite 4410
  • Boston, MA 02135
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Yumanity Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Merger/Acquisition 16-Dec-2022 Completed Generating Revenue
12. PIPE 06-Dec-2022 Completed Generating Revenue
11. PIPE 22-Dec-2020 Completed Generating Revenue
10. Reverse Merger 22-Dec-2020 Completed Generating Revenue
9. Later Stage VC (Series C) 24-Jun-2020 Completed Generating Revenue
8. Debt - PPP 14-Apr-2020 Completed Generating Revenue
7. Mezzanine 31-Dec-2019 Completed Generating Revenue
6. Early Stage VC 29-Jun-2018 Completed Generating Revenue
5. Early Stage VC (Series A) 18-Feb-2016 $51M $51M Completed Startup
4. Accelerator/Incubator 01-Jan-2016 Completed Startup
To view Yumanity Therapeutics’s complete valuation and funding history, request access »

Yumanity Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of transformative brain-penetrating small molecule drugs designed for the treatment of neurodegenerative disea
Drug Discovery
Boston, MA
6 As of 2023

Dublin, Ireland
 

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Yumanity Therapeutics Competitors (40)

One of Yumanity Therapeutics’s 40 competitors is Prothena, a Corporation company based in Dublin, Ireland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Prothena Corporation Dublin, Ireland
Capricor Therapeutics Formerly VC-backed San Diego, CA
CuraSen Venture Capital-Backed San Carlos, CA
Alector Formerly VC-backed South San Francisco, CA
IRulya Therapeutics Formerly VC-backed New Haven, CT
You’re viewing 5 of 40 competitors. Get the full list »

Yumanity Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Yumanity Therapeutics Former Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds
Agent AI Corporation Minority
Alexandria Venture Investments Venture Capital Minority
Altium Capital Management Growth/Expansion Minority
Biogen Corporation Minority
Dolby Family Ventures Venture Capital Minority
You’re viewing 5 of 16 investors. Get the full list »

Yumanity Therapeutics Acquisitions (2)

Yumanity Therapeutics’s most recent deal was a Reverse Merger with Kineta for . The deal was made on 16-Dec-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Kineta 16-Dec-2022 Reverse Merger Drug Discovery
Proteostasis Therapeutics 22-Dec-2020 Merger/Acquisition Drug Discovery
To view Yumanity Therapeutics’s complete acquisitions history, request access »

Yumanity Therapeutics FAQs

  • When was Yumanity Therapeutics founded?

    Yumanity Therapeutics was founded in 2014.

  • Where is Yumanity Therapeutics headquartered?

    Yumanity Therapeutics is headquartered in Boston, MA.

  • What is the size of Yumanity Therapeutics?

    Yumanity Therapeutics has 6 total employees.

  • What industry is Yumanity Therapeutics in?

    Yumanity Therapeutics’s primary industry is Drug Discovery.

  • Is Yumanity Therapeutics a private or public company?

    Yumanity Therapeutics is a Private company.

  • What is Yumanity Therapeutics’s current revenue?

    The current revenue for Yumanity Therapeutics is .

  • How much funding has Yumanity Therapeutics raised over time?

    Yumanity Therapeutics has raised $1.45B.

  • Who are Yumanity Therapeutics’s investors?

    Agent AI, Alexandria Venture Investments, Altium Capital Management, Biogen, and Dolby Family Ventures are 5 of 16 investors who have invested in Yumanity Therapeutics.

  • Who are Yumanity Therapeutics’s competitors?

    Prothena, Capricor Therapeutics, CuraSen, Alector, and IRulya Therapeutics are some of the 40 competitors of Yumanity Therapeutics.

  • When was Yumanity Therapeutics acquired?

    Yumanity Therapeutics was acquired on 16-Dec-2022.

  • Who acquired Yumanity Therapeutics?

    Yumanity Therapeutics was acquired by Kineta.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process